All summary statistics data are available in the National Bioscience Database Center website at (<http://humandbs.biosciencedbc.jp/en/>.) The associated Accession number(s)/URL for our data is as follows: hum0014.v12.T2DMwN.v1 and URL: <https://humandbs.biosciencedbc.jp/hum0014-v12>.

Introduction {#sec001}
============

Diabetic nephropathy is a leading cause of end-stage renal disease (ESRD), and its prevalence is progressively increasing according to the increase of number of patients with diabetes mellitus \[[@pone.0208654.ref001],[@pone.0208654.ref002]\]. Prolonged persistent hyperglycemia is a principal cause of diabetic microvascular complications, but it has been shown that only \~30% of all patients with diabetes develop overt nephropathy, whereas most patients develop diabetic retinopathy 20--30 years after the onset of diabetes \[[@pone.0208654.ref003]\]. In addition, familial clustering of diabetic nephropathy has been observed in both type 1 and type 2 diabetes \[[@pone.0208654.ref004]--[@pone.0208654.ref006]\], implying that genetic factors are involved in the development and/or progression of diabetic nephropathy. Identification of disease susceptibility loci for many common diseases such as type 2 diabetes, has been achieved by the introduction of genome-wide association studies (GWAS). Worldwide efforts to identify susceptibility loci for diabetic nephropathy, however, have not yet met with success so much. Several susceptibility loci to diabetic nephropathy or its related traits which showed their lowest p-values close to or with a genome-wide significance level have been unveiled; rs2268388 in *ACACB* \[[@pone.0208654.ref007]\], rs7583877 in *AFF3* locus, rs17709344 in *RGMA-MCTP2* locus \[[@pone.0208654.ref008]\], rs4972593 in *Sp3-CDCA7* locus \[[@pone.0208654.ref009]\], rs1801239 in *CUBN* locus \[[@pone.0208654.ref010]\], rs161740 in *EPO* locus \[[@pone.0208654.ref011]\]. However, the results have not been conclusive, and thus most susceptibility loci for diabetic nephropathy remain to be un-identified, suggesting heterogeneity of the disease or contribution of non-genetic factors, which have not been taken into account, may produce inconsistent results among the studies.

In this study, to identify novel susceptibility loci to diabetic nephropathy, we performed a GWAS meta-analysis for diabetic nephropathy using existing Japanese GWAS data for patients with type 2 diabetes.

Materials and methods {#sec002}
=====================

Study subjects {#sec003}
--------------

### Discovery stage (Stage-1) {#sec004}

We selected 7,641 individuals having type 2 diabetes registered in Biobank Japan, and divided these patients into two groups (stage-1, set-1); 1) 2,380 nephropathy cases, defined as patients with overt albuminuria or under renal replacement therapy and 2) 5,234 controls with normoalbuminuria and with diabetes duration of 5 years or longer or with diabetic retinopathy. We also used independent patients with type 2 diabetes who were extracted from previously reported GWAS data \[[@pone.0208654.ref012]\], and performed GWAS for diabetic nephropathy (stage-1 set 2, cases, n = 429, controls, n = 358). There was no overlap between set-1 and set-2. Diabetes was diagnosed according to the World Health Organization (WHO) criteria \[[@pone.0208654.ref013]\], and those who were diagnosed as type 1 diabetes, mitochondrial diseases or maturity-onset diabetes of the young were excluded.

### Validation analysis (Stage-2) {#sec005}

We examined independent 2,511 patients with Japanese patients with type 2 diabetes, 1,213 diabetic nephropathy cases and 1,298 controls, from the BioBank Japan that were not included in the discovery stage.

Clinical characteristics of participants for Stage-1 (set-1, set-2) and Stage-2 are shown in [Table 1](#pone.0208654.t001){ref-type="table"}. Genomic DNA was extracted from peripheral leukocytes using the standard procedure. All individuals provided written informed consent to participate in this study.

10.1371/journal.pone.0208654.t001

###### Clinical characteristics of participants.

![](pone.0208654.t001){#pone.0208654.t001g}

                      Stage1                                            Stage2                                                                                     
  ------------------- ------------------------------------------------- ------------- ------------- ------------------------------------------------ ------------- -------------
  n                   2,380                                             5,234         429           358                                              1,213         1,298
  M/F                 1,611/769                                         3,162/2,072   304/125       226/131[\*\*](#t001fn002){ref-type="table-fn"}   833/380       759/539
  Men%                67.6                                              60.4          70.9          63.1                                             68.6          58.5
  age                 65.9 ± 10.5                                       66.3 ± 9.6    67.2 ± 10.0   66.9 ± 9.2                                       63.9 ± 11.0   63.9 ± 10.5
  BMI                 23.9 ± 4.0[\*](#t001fn001){ref-type="table-fn"}   23.6 ± 3.6    23.5 ± 4.0    23.8 ± 3.8                                       24.1 ± 3.9    23.6 ± 3.8
  Diabetes duration   13.1 ± 9.8[\*](#t001fn001){ref-type="table-fn"}   14.4 ± 8.5    13.4 ± 10.2   13.2 ± 10.0                                      12.0 ± 9.5    10.5 ± 8.8

\* P \< 0.01 vs. control

\*\* information of sex for one participant is not available

Genotyping, quality control and imputation in the discovery stage {#sec006}
-----------------------------------------------------------------

Set-1 individuals in stage 1 were genotyped using the Human Omni Express Exome Bead Chip. There were 628,670 autosomal SNPs that passed quality control, a call rate ≥ 0.99, Hardy-Weinberg equilibrium test P ≥ 1 × 10^−6^ in controls and minor allele frequency (MAF) ≥ 0.01. Set-2 samples were genotyped using the Illumina Human 610K SNP array, and 504,984 autosomal SNPs passed the quality control described above and used for further analysis. For sample quality control, we evaluated cryptic relatedness for each sample using an identity-by-state method and removed samples that exhibited second-degree or closer relatedness. We performed principal component analysis to select individuals belong to the major Japanese cluster (Hondo cluster, [S1 Fig](#pone.0208654.s001){ref-type="supplementary-material"}) as reported previously \[[@pone.0208654.ref014]\], and data for 7,614 individuals (2,380 diabetic nephropathy cases and 5,234 controls) in set-1 and 787 individuals (429 diabetic nephropathy cases and 358 controls) in set-2 were used in subsequent analyses. We performed genotype imputation with MACH and Minimac \[[@pone.0208654.ref015],[@pone.0208654.ref016]\] using linkage disequilibrium data in the 1000 Genomes Project (phased JPT, CHB and Han Chinese South data n = 275, March 2012) as reference populations. To evaluate the potential effect of population stratification, we used a quantile-quantile (qq) plot of the observed P-values.

*De novo* genotyping {#sec007}
--------------------

We genotyped 1,213 individuals with diabetic nephropathy and 1,298 controls (Stage-2) registered as type 2 diabetes in BioBank Japan, who were not included in a discovery stage using a multiplex PCR-invader assay \[[@pone.0208654.ref017]\] for SNPs with p values \< 10^−4^ in the meta-analysis. We also genotyped additional 2,123 Japanese patients with type 2 diabetes (902 diabetic nephropathy cases and 1,221 controls), who visited out-patient clinics of Tokai university hospital, Shiga university of medical science hospital, Juntendo university hospital, Kawasaki medical school hospital, Tokyo women's medical university hospital, Iwate Medical University, Toride Kyodo Hospital, Kawai Clinic, Osaka City General Hospital, Chiba Tokusyukai Hospital or Osaka Rosai Hospital.

Genotyping success rates \< 95% or concordance rates \< 99.9% were excluded from the analyses.

Statistical analysis {#sec008}
--------------------

The association between each SNP and diabetic nephropathy was assessed using the logistic regression test with an additive model with or without adjusting for age, sex, and log-transformed body mass index (BMI) using Mach2dat. We combined data from the each GWAS, validation and replication studies using METAL \[[@pone.0208654.ref018]\] as an inverse variance method. Heterogeneity in effect sizes among the studies was evaluated with a Cochran's Q test. Regional association plots were generated using LocusZoom \[[@pone.0208654.ref019]\].

Ethics approval {#sec009}
---------------

The protocol of this study conformed to the provisions of the Declaration of Helsinki and was approved by the ethical committees at the RIKEN Yokohama Institute, Tokai university hospital, Shiga university of medical science, Juntendo university, Kawasaki medical school, Tokyo women's medical university and Iwate Medical University, and the institutional review boards at Toride Kyodo Hospital, Osaka City General Hospital, Chiba Tokusyukai Hospital and Osaka Rosai Hospital.

Results {#sec010}
=======

A meta-analysis of GWAS for diabetic nephropathy in the Japanese patients with type 2 diabetes {#sec011}
----------------------------------------------------------------------------------------------

We obtained genotype data for 7,521,074 SNPs by imputation, and among them, 5,768,242 SNPs those passed quality control (r^2^ \> 0.7) in both studies (Stage-1 set-1 and set-2) were evaluated in this meta-analysis ([Fig 1](#pone.0208654.g001){ref-type="fig"}).

![Outline of this study.\
\* r^2^ \> 0.7 in both studies, SNP; single nucleotide polymorphism, MAF; minor allele frequency, HWE P; Hardy-Weinberg Equilibrium test P, RSQ, r square.](pone.0208654.g001){#pone.0208654.g001}

There was no genomic inflation in the qq plots in the both studies ([S2 Fig](#pone.0208654.s002){ref-type="supplementary-material"}). We selected 77 loci associated with diabetic nephropathy in the meta-analysis (*P* \< 1 × 10^−4^, [S1 Table](#pone.0208654.s004){ref-type="supplementary-material"}), and the associations of the lead SNPs from the 77 loci with DN were examined in an independent case-control study (Stage-2, 1,213 cases and 1,298 controls). In stage-2 analyses, we successfully obtained the genotype data for 65 loci by the multiplex-PCR invader assay. After combining all association data (Stage-1 set-1, set-2 and Stage-2) using the inverse-variance fixed-effects meta-analysis, we found that one SNP locus, rs56094641 in *FTO* at chromosome (Chr) 16, 16q12.2, showed a genome-wide significant association with diabetic nephropathy (*P* = 7.74 × 10^−10^, odds ratio (OR) = 1.23, 95% confidence interval (CI) 1.15−1.31, [Table 2](#pone.0208654.t002){ref-type="table"} and [S2 Table](#pone.0208654.s005){ref-type="supplementary-material"}). The association of the *FTO* locus with overt nephropathy was not affected by an adjustment for age, sex and BMI (rs9936385, r^2^ = 1 with rs56094641, [S3 Table](#pone.0208654.s006){ref-type="supplementary-material"}). We additionally identified suggestive evidence for the associations of six SNP loci with diabetic nephropathy (5.0 × 10^−8^ \< P \< 5.0 × 10^−7^, [Table 2](#pone.0208654.t002){ref-type="table"} and [S2 Table](#pone.0208654.s005){ref-type="supplementary-material"}): rs895157 in *PRCD* (17q25.1, *P* = 7.70 × 10^−8^, OR = 1.28, 95% CI 1.17−1.41), rs10144968 near *RAD51B* (14q24.1--24.2, *P* = 1.22 × 10^−7^, OR = 1.35, 95% CI 1.21−1.51), rs13306536 in *LRP8* (1p32.3, *P* = 2.70 × 10^−7^, OR = 1.33, 95% CI 1.19−1.48), rs7544082 near *TRABD2B* (1p33, *P* = 3.08 × 10^−7^, OR = 1.17, 95% CI 1.10−1.24), rs11101179 in *CHAT* (10q11.2--21.1, *P* = 3.85 × 10^−7^, OR = 1.19, 95% CI 1.11−1.28), rs710375 near *CCNH* (5q14-15, *P* = 3.96 × 10^−7^, OR = 1.21, 95% CI 1.12−1.30). Regional plots for these 7 loci are shown in [S3 Fig](#pone.0208654.s003){ref-type="supplementary-material"}.

10.1371/journal.pone.0208654.t002

###### Association of 7 SNP loci with diabetic nephropathy in Japanese patients with type 2 diabetes.

![](pone.0208654.t002){#pone.0208654.t002g}

  ------------------------------------------------------------------------------------------------------------------
  SNP ID\           Alleles   study            RAF           OR (95%CI)              P                        Phet
  Gene\                                                                                                       
  Chromosome                                                                                                  
  ----------------- --------- ---------------- ------------- ----------------------- ------------------------ ------
  rs56094641        G/A       Stage-1, set-1   0.247/0.211   1.22 (1.13--1.32)       1.19 × 10^−6^            

  *FTO*                       Stage-1, set-2   0.236/0.207   1.19 (0.93--1.52)       0.164                    

  Ch16                        Stage-2          0.252/0.209   1.27 (1.11--1.46)       3.76 × 10^−4^            

                              **Combined**                   **1.23 (1.15--1.31)**   **7.74 × 10**^**−10**^   0.85

  rs895157          C/A       Stage-1, set-1   0.130/0.108   1.28 (1.14--1.43)       2.85 × 10^−5^            

  *PRCD*                      Stage-1, set-2   0.126/0.113   1.14 (0.83--1.58)       0.422                    

  Ch17                        Stage-2          0.140/0.109   1.35 (1.13--1.60)       7.02 × 10^−4^            

                              **Combined**                   **1.28 (1.17--1.41)**   **7.70 × 10**^**−8**^    0.67

  rs10144968        G/T       Stage-1, set-1   0.078/0.062   1.27 (1.11--1.46)       3.75 × 10^−4^            

  *RAD51B*                    Stage-1, set-2   0.083/0.060   1.41 (0.95--2.10)       8.48 × 10^−2^            

                              Stage-2          0.078/0.051   1.58 (1.25--1.99)       1.15 × 10^−4^            

                              **Combined**                   **1.35 (1.21--1.51)**   **1.22 × 10**^**−7**^    0.28

  rs13306536        T/C       Stage-1, set-1   0.089/0.068   1.27 (1.11--1.46)       3.75 × 10^−4^            

  *LRP8*                      Stage-1, set-2   0.068/0.075   0.87 (0.58--1.30)       0.496                    

  Ch1                         Stage-2          0.076/0.058   1.35 (1.08--1.69)       1.15 × 10^−4^            

                              **Combined**                   **1.33 (1.19--1.48)**   **2.70 × 10**^**−7**^    0.1

  rs7544082         A/C       Stage-1, set-1   0.525/0.492   1.18 (1.09--1.27)       3.22 × 10^−5^            

  *TRABD2B*                   Stage-1, set-2   0.550/0.514   1.15 (0.77--1.72)       0.164                    

  Ch1                         Stage-2          0.552/0.514   1.16 (1.04--1.31)       8.70 × 10^−3^            

                              **Combined**                   **1.17 (1.10--1.24)**   **3.08 × 10**^**−7**^    0.97

  rs11101179        C/T       Stage-1, set-1   0.231/0.197   1.22 (1.12--1.33)       2.23 × 10^−6^            

  *CHAT*                      Stage-1, set-2   0.205/0.205   1.00 (0.77--1.31)       0.977                    

  Ch10                        Stage-2          0.226/0.198   1.17 (1.02--1.34)       2.10 × 10^−2^            

                              **Combined**                   **1.19 (1.11--1.28)**   **3.85 × 10**^**−7**^    0.37

  rs710375          C/T       Stage-1, set-1   0.201/0.169   1.24 (1.14--1.36)       2.23 × 10^−6^            

  *CCNH-TMEM161B*             Stage-1, set-2   0.197/0.154   1.38 (1.04--1.77)       0.977                    

  Ch5                         Stage-2          0.187/0.176   1.08 (0.93--1.24)       2.10 × 10^−2^            

                              **Combined**                   **1.21 (1.12--1.30)**   **3.96 × 10**^**−7**^    0.16
  ------------------------------------------------------------------------------------------------------------------

Replication study {#sec012}
-----------------

We examined the association of rs56094641 in *FTO* with overt nephropathy in 2,123 Japanese patients with type 2 diabetes (cases n = 902, controls n = 1,221). As shown in [Table 3](#pone.0208654.t003){ref-type="table"}, rs56094641 in *FTO* showed the same direction of effect with the original finding in the discovery stage. The association of rs56094641 in *FTO* with overt nephropathy was still genome-wide significant level after integration of all association data (*P* = 7.62 × 10^−10^, OR = 1.21, 95% CI 1.14−1.29, [Table 3](#pone.0208654.t003){ref-type="table"}) though the association was not statistically significant in the replication study alone (*P* = 0.258, OR = 1.11, 95% CI 0.93−1.32, [Table 3](#pone.0208654.t003){ref-type="table"}).

By *in silico* replication using SUMMIT consortium data for type 2 diabetes, the association of *FTO* variants with diabetic nephropathy was not replicated in European patients with type 2 diabetes ([Table 3](#pone.0208654.t003){ref-type="table"}).

10.1371/journal.pone.0208654.t003

###### Replication studies for 7 loci associated with diabetic nephropathy.

![](pone.0208654.t003){#pone.0208654.t003g}

  ----------------------------------------------------------------------------------------------
  SNP ID\      Alleles   Ethnicity   RAF           OR (95%CI)           P                Phet
  gene                                                                                   
  ------------ --------- ----------- ------------- -------------------- ---------------- -------
  rs56094641   G/A       Japanese    Discovery     1.23 (1.15--1.31)    7.74 × 10^−10^   

  *FTO*                              Replication   1.11 (0.93--1.32)    0.258            

                                     Combined      1.21 (1.14--1.29)    7.62 × 10^−10^   0.67

                         Europeans                 1.06 (1.19--0.95)    0.300            

  rs895157     C/A       Japanese    Discovery     1.28 (1.17--1.41)    7.70 × 10^−8^    

  *PRCD*                             Replication   0.96 (0.77--1.21)    0.748            

                                     Combined      1.23 (1.13--1.34)    1.15 × 10^−6^    0.11

                         Europeans                 0.92 (0.80--1.06)    0.195            

  rs10144968   G/T       Japanese    Discovery     1.35 (1.21--1.51)    1.22 × 10^−7^    

  *RAD51B*                           Replication   1.04 (0.76--1.41)    0.808            

                                     Combined      1.31 (1.18--1.45)    4.23 × 10^−7^    0.17

                         Europeans                 0.91 (0.80--1.03)    0.289            

  rs13306536   T/C       Japanese    Discovery     1.33 (1.19--1.48)    2.70 × 10^−7^    

  *LRP8*                             Replication   0.98 (0.72--1.34)    0.914            

                                     Combined      1.30 (1.16--1.42)    1.38 × 10^−6^    0.05

                         Europeans                 N/A                  N/A              

  rs7544082    A/C       Japanese    Discovery     1.17 (1.10--1.24)    3.08 × 10^−7^    

  *TRABD2B*                          Replication   0.99 (0.86--1.15)    0.946            

                                     Combined      1.16 (1.04--1.31)    2.58 × 10^−6^    0.24

                         Europeans                 N/A                  N/A              

  rs11101179   C/T       Japanese    Discovery     1.19 (1.11--1.28)    3.85 × 10^−7^    

  *CHAT*                             Replication   0.92 (0.77--1.10)    0.365            

                                     Combined      1.15 (1.08--1.23)    9.36 × 10^−6^    0.03

                         Europeans                 N/A                  N/A              

  rs710375     C/T       Japanese    Discovery     1.21 (1.12--1.30)    3.96 × 10^−7^    

  *CCNH*                             Replication   0.85 (0.70--1.03)    9.86 × 10^−2^    

                                     Combined      1.16 (1.08--1.24)    3.02 × 10^−5^    0.002

                         Europeans                 1.12 (0.999--1.12)   3.58 × 10^−2^    
  ----------------------------------------------------------------------------------------------

N/A, data is not available

Evaluation of previously reported loci {#sec013}
--------------------------------------

We reflected our results (meta-analysis of Stage-1 set-1 and set-2) on previously- reported susceptibility loci to overt nephropathy. There was no overlap between the above seven SNP loci and 21 loci from previously-reported GWAS for susceptibility to overt nephropathy ([S4 Table](#pone.0208654.s007){ref-type="supplementary-material"}). None of the SNPs in the original reports showed significant association with overt nephropathy in the discovery stage (*P* \> 2.38 x 10^−3^ = 0.05/21). Regional lead SNPs within the *ELMO1*, *RGMA*-*MCTP2*, *ERBB4* and *SP3*-*CDCA7* in the discovery stage attained the threshold of the correction of multiple testing error.

Discussion {#sec014}
==========

From a result of GWAS meta-analysis for diabetic nephropathy followed by validation studies in Japanese patients with type 2 diabetes, which comprising in 4,022 cases and 6,890 controls, we identified significant association between rs56094641 in *FTO* and susceptibility to diabetic nephropathy in Japanese patients with type 2 diabetes.

*FTO* locus has been repeatedly reported to be associated with obesity and/or adiposity \[[@pone.0208654.ref020]\], and, in this study, we have shown that the risk allele for obesity was significantly associated with susceptibility to diabetic nephropathy in Japanese patients with type 2 diabetes.

Smemo *et al*. mentioned that obesity-associated noncoding sequences within *FTO* are functionally connected, at megabase distances, with the homeobox gene *IRX3* \[[@pone.0208654.ref021]\]. *IRX3* is a member of the Iroquois homeobox gene family and plays a role in an early step of neural development \[[@pone.0208654.ref022]\]. Members of this family including *IRX3* and *IRX5* appear to play multiple roles during pattern formation of vertebrate embryos \[[@pone.0208654.ref023]\]. However, there is no evidence showing functional link between *IRX3*/*IRX5* and diabetic nephropathy.

Obesity has been recognized as an important risk factor for chronic kidney disease (CKD) \[[@pone.0208654.ref024],[@pone.0208654.ref025]\]. The incidence of obesity has actualized an increase the number of patients with obesity-related glomerulopathy and proteinuria \[[@pone.0208654.ref026]\]. Furthermore, obesity has been reported to be an independent risk factor for ESRD by a large historical cohort study of 177,570 adults after adjustment for multiple epidemiologic and clinical conditions including diabetes \[[@pone.0208654.ref027]\] Moreover, a *FTO* variant, rs17817449, which are in absolute linkage disequilibrium to rs56094641, was shown to be associated with ESRD \[[@pone.0208654.ref028]\], suggesting *FTO* variants confer susceptibility to CKD/ESRD through the mechanisms mediated by obesity/adipocity.

In European patients with type 1 or type 2 diabetes, a genetic risk score constructed from confirmed obesity related SNP loci was associated with diabetic nephropathy \[[@pone.0208654.ref029]--[@pone.0208654.ref031]\], although *FTO* variant alone did not have significant effect on any of renal phenotype. Therefore, our report is the first to show a robust association of *FTO* variant with diabetic nephropathy. In addition, adjustment for BMI did not influence the association of the SNP with diabetic nephropathy in this study, suggesting that the SNP gets involved in susceptibility to diabetic nephropathy through the mechanism other than increasing BMI. Values of BMI used in this study, however, were obtained after making diagnosis of type 2 diabetes and some therapeutic interventions might affect the BMI values used in this study. Therefore, we might underestimate the effects of BMI on susceptibility to diabetic nephropathy.

We also obtained six SNP loci, which have shown borderline associations with overt nephropathy at the discovery stage ([Table 1](#pone.0208654.t001){ref-type="table"}: 5 × 10^−8^ \< combined *P* ≤ 5 × 10^−7^), but all candidate SNPs did not show significant effects in the replication stage in an independent Japanese case-control study ([Table 3](#pone.0208654.t003){ref-type="table"}). In this study, we could not replicate almost all of variants identified by meta-analysis of stage 1 and stage 2 in the additional dataset with a comparable sample size with stage 2 GWAS. Although genome-wide SNPs data are not available for individuals in the replication stage, all samples for the replication stage were collected in the Japan main-island, and it has been shown individuals living in Japan main-island are genetically homogeneous \[[@pone.0208654.ref014]\]; therefore, we think there is no evidence for population heterogeneity between the discovery stage and the replication stage.

We further performed a GWAS meta-analysis for diabetic nephropathy including patients with microalbuminuria as cases, and found that rs56094641 in *FTO* was significantly associated with diabetic nephropathy also in this analysis (*P* = 2.40 × 10^−9^, OR = 1.18, 95% CI 1.15−1.31, [S5](#pone.0208654.s008){ref-type="supplementary-material"} and [S6](#pone.0208654.s009){ref-type="supplementary-material"} Tables). However, the association was not stronger than that in the analysis using overt nephropathy as cases, suggesting the *FTO* variant was associated with advanced stages of diabetic nephropathy.

Our study has some limitations. Firstly, the detail clinical information, i.e. blood pressure, Hemoglobin A1c, lipid profiles, prescription of antihypertensive treatments, was not available in many participants in Stage-1 samples. It means that we cannot exclude the possibility that the association of the SNP with diabetic nephropathy is mediated by some risk factors except age, sex and BMI. Second, by *in silico* replication using SUMMIT consortium data for type 2 diabetes, the association of *FTO* variants with diabetic nephropathy was not replicated in European patients with type 2 diabetes ([Table 3](#pone.0208654.t003){ref-type="table"}, [S7 Table](#pone.0208654.s010){ref-type="supplementary-material"}), and the association of *FTO* variants with diabetic nephropathy showed a genome-wide significant association only in a joint analysis for the discovery stage; therefore, these observations may not be in line with standards for GWA studies; further study, such as a large-scaled longitudinal study, is required to elucidate the association of *FTO* locus with diabetic nephropathy.

Conclusions {#sec015}
===========

We performed GWAS for diabetic nephropathy in Japanese patients with type 2 diabetes. One SNP locus, *FTO* locus, showed a significant association with susceptibility to diabetic nephropathy, and the association attained a genome-wide significant level. Further studies are required to confirm the association of this locus with diabetic nephropathy.
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